S.3269 - Cannabidiol Research Expansion Act114th Congress (2015-2016)
|Sponsor:||Sen. Feinstein, Dianne [D-CA] (Introduced 07/14/2016)|
|Committees:||Senate - Judiciary|
|Latest Action:||07/14/2016 Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5169) (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.3269 — 114th Congress (2015-2016)All Information (Except Text)
Introduced in Senate (07/14/2016)
Cannabidiol Research Expansion Act
This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted.
The bill expands the authority for: (1) conducting medical research on cannabidiol, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes.
Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients.
The bill terminates four years after enactment.